Beta-2 glycoprotein 1 antibody is an autoantibody that is associated with inappropriate blood clotting. This test detects and measures beta-2 glycoprotein 1 antibodies in the blood.

It helps diagnose: Antiphospholipid syndrome (APS) The cause of an unexplained blood clot (thrombotic episode)

Normal: β2 GPI IgG ≤ 20 SGU U/mL. β2 GPI IgM ≤ 20 SMU U/mL

The Beta-2 Glycoprotein IgM test is used to detect the presence of IgM antibodies directed against beta-2 glycoprotein in the blood. This test is often ordered in the context of evaluating autoimmune diseases, particularly antiphospholipid syndrome (APS), which is characterized by abnormal blood clotting and an increased risk of thrombosis. Here's how to interpret the results of a Beta-2 Glycoprotein IgM test: Negative Result: A negative result indicates the absence of detectable IgM antibodies against beta-2 glycoprotein in the blood. In the context of APS evaluation, a negative result suggests that IgM antibodies to beta-2 glycoprotein are not contributing to the patient's clinical condition. However, it's important to note that a negative result does not completely rule out APS, as other antibodies (e.g., IgG antibodies to beta-2 glycoprotein) and clinical criteria are also considered in the diagnosis. Positive Result: A positive result indicates the presence of IgM antibodies against beta-2 glycoprotein in the blood. Elevated levels of IgM antibodies to beta-2 glycoprotein may be associated with autoimmune disorders such as APS. In the context of APS, the presence of IgM antibodies to beta-2 glycoprotein, along with other laboratory and clinical findings, may support the diagnosis of APS. Interpretation: Interpretation of the Beta-2 Glycoprotein IgM test results should be done in conjunction with the patient's clinical history, symptoms, and other laboratory findings. Diagnosis of APS typically requires a combination of clinical criteria (e.g., history of thrombosis, pregnancy complications) and laboratory criteria (e.g., presence of antiphospholipid antibodies). Other conditions, such as infections and other autoimmune diseases, can also lead to the production of IgM antibodies against beta-2 glycoprotein, so clinical correlation is essential. Further Evaluation: Additional laboratory tests, including other antiphospholipid antibodies (e.g., IgG antibodies to beta-2 glycoprotein, lupus anticoagulant) and coagulation studies, may be necessary to further evaluate the possibility of APS. Repeat testing and clinical follow-up may be needed to confirm the diagnosis and monitor disease activity over time.

Blood